Achilles Therapeutics
Stock Forecast, Prediction & Price Target
Achilles Therapeutics Financial Estimates
Achilles Therapeutics Revenue Estimates
Achilles Therapeutics EBITDA Estimates
Achilles Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
Net Income
% change YoY
| $-61.09M N/A | $-71.17M -16.49% | $-69.66M 2.12% | Avg: $-88M Low: $-83.54M High: $-4.79M avg. -26.31% | Avg: $-118.4M Low: $-109.92M High: $-109.92M avg. -34.54% | Avg: $-128.71M Low: $-128.71M High: $-128.71M avg. -8.71% | Avg: $-150.69M Low: $-150.69M High: $-150.69M avg. -17.08% |
EBITDA
% change YoY
| $-60.90M N/A | $-74.69M -22.63% | $-70.44M 5.69% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$2.13 N/A | -$1.82 14.55% | -$1.74 4.39% | Avg: -$1.11 Low: -$2.09 High: -$0.12 avg. 36.49% | Avg: -$2.75 Low: -$2.75 High: -$2.75 avg. -148.86% | Avg: -$3.22 Low: -$3.22 High: -$3.22 avg. -17.09% | Avg: -$3.77 Low: -$3.77 High: -$3.77 avg. -17.08% |
Operating Expenses
% change YoY
| $64.19M N/A | $78.38M 22.10% | $75.25M -3.99% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Achilles Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -21.66% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -83.54M, average is -88M and high is -4.79M.
What is Achilles Therapeutics stock revenue growth forecast?
We have gathered data from 1 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Achilles Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -36.63% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$2.09, average is -$1.11 and high is $-0.12.
What is the best performing analyst?
In the last twelve months analysts have been covering Achilles Therapeutics stock. The most successful analyst is Joseph Catanzaro.